HomeCompareHBPCF vs MRK

HBPCF vs MRK: Dividend Comparison 2026

HBPCF yields 115.61% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 HBPCF wins by $7.17M in total portfolio value
10 years
HBPCF
HBPCF
● Live price
115.61%
Share price
$1.73
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$7.23M
Annual income
$2,676,132.53
Full HBPCF calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — HBPCF vs MRK

📍 HBPCF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodHBPCFMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, HBPCF + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
HBPCF pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

HBPCF
Annual income on $10K today (after 15% tax)
$9,826.59/yr
After 10yr DRIP, annual income (after tax)
$2,274,712.65/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, HBPCF beats the other by $2,266,384.24/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of HBPCF + MRK for your $10,000?

HBPCF: 50%MRK: 50%
100% MRK50/50100% HBPCF
Portfolio after 10yr
$3.64M
Annual income
$1,342,965.33/yr
Blended yield
36.86%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

HBPCF
No analyst data
Altman Z
17.7
Piotroski
1/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

HBPCF buys
0
MRK buys
0
No recent congressional trades found for HBPCF or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricHBPCFMRK
Forward yield115.61%2.76%
Annual dividend / share$2.00$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$7.23M$56.8K
Annual income after 10y$2,676,132.53$9,798.13
Total dividends collected$6.55M$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: HBPCF vs MRK ($10,000, DRIP)

YearHBPCF PortfolioHBPCF Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$22,261$11,560.69$11,206$366.19+$11.1KHBPCF
2$47,870$24,051.31$12,650$502.35+$35.2KHBPCF
3$99,558$48,337.27$14,407$694.19+$85.2KHBPCF
4$200,481$93,953.00$16,585$967.82+$183.9KHBPCF
5$391,330$176,815.76$19,342$1,363.89+$372.0KHBPCF
6$741,281$322,558.19$22,913$1,947.19+$718.4KHBPCF
7$1,364,208$571,036.96$27,662$2,823.89+$1.34MHBPCF
8$2,441,853$982,150.40$34,159$4,173.35+$2.41MHBPCF
9$4,255,766$1,642,983.32$43,337$6,308.80+$4.21MHBPCF
10$7,229,802$2,676,132.53$56,776$9,798.13+$7.17MHBPCF

HBPCF vs MRK: Complete Analysis 2026

HBPCFStock

Helix BioPharma Corp. operates as an immune-oncology company in Canada. The company is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. It has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging. The company is headquartered in Toronto, Canada.

Full HBPCF Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this HBPCF vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

HBPCF vs SCHDHBPCF vs JEPIHBPCF vs OHBPCF vs KOHBPCF vs MAINHBPCF vs JNJHBPCF vs ABBVHBPCF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.